Abstract
The UK Biobank study has produced thousands of brain imaging-driven phenotypes (IDPs) collected from more than 40,000 genotyped individuals so far, facilitating the investigation of genetic and imaging biomarkers for brain disorders. Motivated by efforts in genetics to integrate gene expression levels with genome-wide association studies (GWASs), recent methods in imaging genetics adopted an instrumental variable (IV) approach to identify causal IDPs for brain disorders. However, several methodological challenges arise with existing methods in achieving causality in imaging genetics, including horizontal pleiotropy and high dimensionality of candidate IVs. In this work, we propose testing the causality of each brain modality (i.e., structural, functional, and diffusion MRI) for each gene as a useful alternative, which offers an enhanced understanding of the roles of genetic variants and imaging features on behavior by controlling for the pleiotropic effects of IDPs from other imaging modalities. We demonstrate the utility of the proposed method by using Alzheimer’s GWAS data from the UK Biobank and the International Genomics of Alzheimer’s Project (IGAP) study. Our method is implemented using summary statistics, which is available on GitHub.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by the McLaughlin Centre (accelerator grant). DF was supported by The Koerner Family Foundation, The Krembil Foundation, The CAMH Foundation, and the Canadian Institutes of Health Research. JG was partially supported by the Natural Sciences and Engineering Research Council of Canada (RGPIN-2021-03734), and the University of Toronto's Data Science Institute, and the Connaught Fund. JYP was partially supported by the Natural Sciences and Engineering Research Council of Canada (RGPIN-2022-04831), and the University of Toronto's Data Science Institute, and the Connaught Fund.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used GWAS summary statistics (https://www.niagads.org/datasets/ng00036, https://www.nealelab.is/uk-biobank, and https://open.win.ox.ac.uk/ukbiobank/big40/) and 1000 Genome Project data (https://www.internationalgenome.org/) that are publicly available in the provided links. In addition, simulated data was generated by using R.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos